Pharmaceutical Executive March 16, 2020
Jill Wechsler

Now officially a worldwide pandemic, the biomedical research community is rushing to develop treatments and preventives to halt the spread and severity of the COVID-19 virus. Political infighting has stymied an effective response in the US, with much finger-pointing on all sides. As the severity of the disease becomes more starkly apparent, schools and communities have shut down and cancellations have hit most travel, sports, and business and professional meetings.

An efficient effort by the US health care system to identify and isolate infected individuals has been undermined by a lack of fast and available diagnostics, and remedies have been derailed by political missteps and administrative failings. Short supplies of test kits and of reagents have forced clinics and hospitals...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Provider, Supply Chain, Technology, Trends
The (Upper) Case For Capitalizing Multiracial
2 nursing staff models that could reduce patient safety
Partnering to Provide Digital-Driven Nutrition Services: Attane Health and Anthem Blue Cross Blue Shield
Fauci allies, Covid vaccine officials get ax at NIH
Mapped: The most (and least) healthy cities in America

Share This Article